How two new Foresite deals build on the firm’s investment in Relay, with computational tech and AI opening doors

Two new deals by Foresite build on a theme that began with its investment in Relay, illustrating how the firm is thinking about applying computing and visualization technologies to protein dynamics, with the goal of analyzing newly available data to solve problems in drug discovery and development.

Last month, the firm invested in Eikon Therapeutics Inc., a super-resolution microscopy company that has landed Roger Perlmutter, the longtime Merck & Co. Inc. (NYSE:MRK) R&D executive, as its CEO; and Interline Therapeutics Inc., which creates maps of protein communities to suss out how their interactions are associated with disease states. Both companies use artificial intelligence tools to guide discovery...